RANBAXY LAUNCHES GENERIC DRUGS IN MALAYSIA

Ranbaxy Laboratories has announced that its wholly owned subsidiary, Ranbaxy Malaysia, has launched the first generic Atorvastatin, a statin, under the brand name Storvas in Malaysia. The product will be sold in dosage forms of 10, 20 and 40 mg. The company had received approval from the Drugs Control Authority of Malaysia to manufacture and market the product, which will by produced at Ranbaxy's facility there.

In July Ranbaxy became the first company to receive approval from Malaysia to market generic oseltamavir and was awarded a contract from the government. The product, marketed by Ranbaxy as Fluhalt, is an antiviral used for treatment of H5N1 virus and is available as 75-mg capsules. Fluhalt is being supplied to all government hospitals, clinics and pharmacies in Malaysia.

"It is our constant endeavor to offer affordable and safe generics of high quality to the patients in Malaysia and provide support to the government's healthcare plan," said T. Jeyabalan, Ranbaxy Malaysia's managing director.